Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VULCANIZE-II: NACT vs Chemoradiation for Vulvar Carcinoma
NCT05905315Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and carboplatin in vulvar carcinoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Loco-regional control after 24 months per completed treatment including salvage treatment. Started Jan 2024; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
vulvar carcinoma
Beyond the preview
Go deeper on NCT05905315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905315.